Metz, Martin http://orcid.org/0000-0002-4070-9976
Sussman, Gordon
Gagnon, Rémi
Staubach, Petra
Tanus, Tonny
Yang, William H.
Lim, Jeremy J.
Clarke, Holly J.
Galanter, Joshua
Chinn, Leslie W.
Chu, Tom
Teterina, Anastasia
Burgess, Tracy
Haddon, D. James
Lu, Timothy T.
Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Funding for this research was provided by:
Genentech
Article History
Received: 19 February 2021
Accepted: 10 September 2021
First Online: 8 November 2021
Competing interests
: M. Metz reports receiving honoraria as a speaker and/or consultant for Amgen, Aralez, argenx, Moxie, Novartis, Roche, Sanofi, Shire and Uriach. G.S. reports serving as a principal investigator for Genentech, Novartis, CSL Behring, Shire, Sanofi, AstraZeneca, DBV Technologies, Aimmune Therapeutics, Greencross, Kedrion, ALK-Abelló, Stallergenes, LEO Pharma, Amgen, BioCryst, Regeneron and Cliantha; serving on advisory boards for Novartis, CSL Behring, Shire, Sanofi, Aralez, Pediapharm and AstraZeneca; serving as a speaker for Novartis, Sanofi, Aralez, Pediapharm, Genentech and AstraZeneca; receiving personal fees from Novartis, CSL Behring, Shire, Sanofi, Aralez, Pediapharm and AstraZeneca. T.T. reports receiving funding from Genentech to his institution for the conduct of this study. W.H.Y. reports receiving speakers’ fees from Novartis, Merck, CSL Behring, Takeda (Shire) and AstraZeneca; serving on advisory boards for Novartis, Takeda (Shire), CSL Behring, Sanofi, BioCryst and Merck; and receiving research grants from Novartis, Takeda (Shire), CSL Behring, BioCryst, AstraZeneca, Regeneron, Sanofi, Genentech, Glenmark, AnaptysBio, Dermira, Galderma, ALK, DBV Technologies, Aimmune Therapeutics, Colgene and Pharming. J.J.L., H.J.C., J.G., L.W.C., T.C., T.B., D.J.H. and T.T.L. are current or former employees of Genentech, a member of the Roche group, at the time this work was performed and own/owned Roche stock and/or options. L.W.C. is currently an employee of Principia Biopharma and owns Principia Biopharma stock and/or options. D.J.H. owns Principia Biopharma stock. T.T.L. is currently an employee of DiCE Molecules. M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Amgen, Aralez, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech, GI Innovation, Innate Pharma, Kyowa Kirin, LEO Pharma, Lilly, Menarini, Moxie, Merck Sharp & Dohme, Novartis, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB and Uriach. R.G. and P.S. declare no competing interests.